MedTrace Logo

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

NCT01382745 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2013-01-28

No results posted yet for this study

Summary

The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.

Conditions

  • Squamous Cell Carcinoma of Anal Canal

Interventions

DRUG

Nimotuzumab

200mg Nimotuzumab once a week for 12 weeks

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions

Sponsors & Collaborators

  • YM BioSciences

    collaborator INDUSTRY

  • Dr. Te Vuong

    lead OTHER

Principal Investigators

  • Te Vuong, MD · Jewish General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2021-09-30
Completion
2022-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01382745 on ClinicalTrials.gov